Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (181-190 of 238) with videos related to

Pageof 24
Sort By:
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Cancer Cell|December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer modelsRyan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.
The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
Molecular Cancer Therapeutics|August 24, 2019
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant CancersHuai-Xiang Hao, Hongyun Wang, Chen Liu, et al.
Cancer Discovery|March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerLuc Friboulet, Nanxin Li, Ryohei Katayama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapyThomas J Lynch, George R Blumenschein, Jeffrey A Engelman, et al.
The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
Cancer Discovery|December 7, 2011
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitorsAnthony C Faber, Ryan B Corcoran, Hiromichi Ebi, et al.
Cancer Discovery|October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Cancer Research|August 5, 2020
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor XenograftsAdam C Palmer, Deborah Plana, Hui Gao, et al.
Pageof 24

Showing results (181-190 of 238) with videos related to

Sort By:
Pageof 24
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Cancer Cell|December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer modelsRyan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.
The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
Molecular Cancer Therapeutics|August 24, 2019
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant CancersHuai-Xiang Hao, Hongyun Wang, Chen Liu, et al.
Cancer Discovery|March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerLuc Friboulet, Nanxin Li, Ryohei Katayama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapyThomas J Lynch, George R Blumenschein, Jeffrey A Engelman, et al.
The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
Cancer Discovery|December 7, 2011
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitorsAnthony C Faber, Ryan B Corcoran, Hiromichi Ebi, et al.
Cancer Discovery|October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Cancer Research|August 5, 2020
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor XenograftsAdam C Palmer, Deborah Plana, Hui Gao, et al.
Pageof 24